RemeGen (09995.HK) Receives USD650M Upfront Payment from AbbVie for RC148

News Sharing

For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields

Receiver*

Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com

Your email address*

Content Sharing

RemeGen (09995.HK) Receives USD650M Upfront Payment from AbbVie for RC148

RemeGen (09995.HK) announced that it has received an upfront payment of USD650 million from AbbVie (through its holding company) under an exclusive licensing agreement for RC148, a...

Reset

Send

The window will close in 5 seconds

RemeGen (09995.HK) Receives USD650M Upfront Payment from AbbVie for RC148

Recommend

Positive

Negative

SHORT SELL

STOCK INFO

aacat by AASTOCKS
Open a new trading account to get NVDA share!

RemeGen (09995.HK) -0.500 (-0.478%) Short selling $31.58M; Ratio 10.380% announced that it has received an upfront payment of USD650 million from AbbVie (through its holding company) under an exclusive licensing agreement for RC148, a novel PD-1/VEGF bispecific antibody independently developed by the company. The collaboration between the two parties is currently progressing smoothly. (ha/da)(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2026-04-24 16:25.)

This article was automatically translated by AI, the Chinese version should be considered the authoritative version. AASTOCKS.com Limited does not guarantee its accuracy or completeness and accepts no liability for any damages or losses arising from the use of this translation.

Auto-translated by AI

View Original Text

AASTOCKS Financial News

Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.